IlluminaWBO:ILMN -2.62%70 Interest Coverage is 8.71 as of Mar. 2026, which is 40% below its 10-year median of 14.56. GuruFocus rates WBO:ILMN with a GF Score™ of 70/100 and a GF Value™ of €115.60 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 95 Medical Diagnostics & Research companies, Illumina ranks worse than 52.63% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Illumina's
Operating Income
for the
three
months ended in Mar. 2026 was €181 Mil. Illumina's Interest Expense for the
three
months ended in Mar. 2026 was €-21 Mil.
Illumina's interest coverage for the quarter that ended in Mar. 2026 was 8.71.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Illumina's Interest Coverage or its related term are showing as below:
WBO:ILMN'
s Interest Coverage Range Over the Past 10 Years
Min: 6 Med: 14.56 Max: 18.94
Current: 8.61
WBO:ILMN's Interest Coverage is ranked worse than 52.63% of 95
companies
in the Medical Diagnostics & Research industry
Industry Median: 9.05
vs WBO:ILMN: 8.61
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Illumina Interest Coverage Related Terms
Illumina Interest Coverage Historical Data
* Premium members only.
The historical data trend for Illumina's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
WBO:ILMN vs MTD, DGX, LH: Interest Coverage Comparison
For the Diagnostics & Research subindustry, Illumina's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Illumina's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Illumina (WBO:ILMN) has a Interest Coverage of 8.71 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Illumina and its competitors. This is 40% below median its historical median of 14.56. Over the past decade, Illumina's Interest Coverage has ranged from 6.00 to 18.94. According to the industry distribution chart, Illumina ranks #50 out of 95 companies in the Medical Diagnostics & Research industry, placing it in the top 52.6%.
Is Illumina's Interest Coverage too high?
Illumina's current Interest Coverage of 8.71 is 40% below median its 10-year median of 14.56. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 18.94. The Medical Diagnostics & Research industry median Interest Coverage is 9.05. Illumina's value of 8.71 is 3.8% below this industry median. Based on the distribution chart, Illumina ranks #50 out of 95 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Illumina has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Illumina's Interest Coverage compare to MTD and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Illumina ranks #50 out of 95 companies for Interest Coverage. This places Illumina in the lower half of its industry. The industry median Interest Coverage is 9.05. Illumina's value of 8.71 is 3.8% below this benchmark. Historically, Illumina's own Interest Coverage has ranged from 6.00 to 18.94 over the past decade. While the company's 10-year median is 14.56 vs. the industry median of 9.05, Illumina has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 9.05, based on 95 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Illumina's current Interest Coverage of 8.71 is 3.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Illumina and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 9.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Illumina's current Interest Coverage is 8.71, which is 40% below median its own 10-year median of 14.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Based on GuruFocus' analysis, Illumina (WBO:ILMN) is currently considered Significantly Overvalued. The stock's GF Value™ is €115.60, compared to a current price of €154.82 — trading 33.9% above its estimated fair value. The current Interest Coverage is 8.71, which is 40% below median its 10-year median of 14.56 and 3.8% below the Medical Diagnostics & Research industry median of 9.05. Illumina's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Illumina (WBO:ILMN), the current Interest Coverage is 8.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Illumina (WBO:ILMN) Overvalued in 2026?
Based on GuruFocus' analysis, Illumina stock appears to be overvalued.
The current stock price of €154.82 is trading 33.9% above its estimated GF Value™ of €115.60.
GuruFocus considers Illumina to be Significantly Overvalued.
Key valuation signals for WBO:ILMN:
Interest Coverage: 8.71 (40% below median its 10-year median of 14.56)
GF Value™: €115.60 vs. price of €154.82 (33.9% above fair value)
Industry Position: 3.8% below the Medical Diagnostics & Research median (#50 of 95)
No single metric tells the full story. See the WBO:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
70GF Score
Get the complete analysis for WBO:ILMN
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:ILMN has been successfully added to your 
